The U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee has a lot to discuss Nov. 17, but only one voting question: Does the evidence demonstrate that Merck & Co. Inc.’s gefapixant provides a clinically meaningful benefit to adults with refractory or unexplained chronic cough?
Based on the researchers’ findings, gefapixant provides small benefits in cough severity, cough frequency, and cough-specific quality of life in patients with refractory or unexplained chronic coughs.
People who suffer from chronic cough may be offered new hope thanks to a drug that can ease the symptom. Researchers suggest the medication called gefapixant ha.
People who suffer from chronic cough may be offered new hope thanks to a drug that can ease the symptom. Researchers suggest the medication called gefapixant ha.
People who suffer from chronic cough may be offered new hope thanks to a drug that can ease the symptom. Researchers suggest the medication called gefapixant ha.